The anti CD47 drugs market has witnessed significant growth owing to the growing prevalence of various types of cancer worldwide. CD47 is an immune checkpoint protein expressed by many cancer cells to evade phagocytosis by macrophages. Anti CD47 therapy involves blocking the CD47 protein to allow macrophages to identify and destroy cancer cells more effectively. Some key advantages of anti CD47 drugs include targeted therapeutic action, improved survival rates, and minimal side effects. With rising cancer incidence accompanied by limitations of existing therapies, the demand for more effective and targeted treatment options like anti CD47 drugs is increasing substantially.
The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031.
Key Takeawaysoperating in the anti CD47 drugs market are Trillium Therapeutics, Aurelius Biotherapeutics, Forty Seven Inc, Surface Oncology, and I-Mab Biopharma.
Some major opportunities in the market include emerging combination therapies with anti CD47 drugs, ongoing clinical trials evaluating safety and efficacy, and potential new indications beyond oncology. Geographically, North America is expected to dominate the Anti CD47 Drugs Market owing to high cancer burden, availability of advanced healthcare facilities, and growing R&D investments by key players. However, Asia Pacific is likely to exhibit the fastest growth over the forecast period due to rising healthcare expenditures, rapid economic development and increasing focus on cancer treatment in the region.
Market Drivers The global anti CD47 drugs market is driven by the growing prevalence of cancer and rising geriatric population. As per WHO, cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. Moreover, anti CD47 drugs have demonstrated promising results with manageable safety risks in clinical trials, which is further propelling their demand. Ongoing research to expand therapeutic applications and evaluate combination regimens with anti CD47 drugs is also boosting their market growth substantially.
PEST Analysis
Political: There is currently no regulation regarding anti-CD47 drug development and approval pathway. Regulations need to be defined to streamline the approval process.
Economic: High development costs and risk of failure increase pressure on drug developers to price anti-CD47 drugs high. However, payers and governments may resist high prices limiting revenues.
Social: Growing awareness about cancer and availability of new treatment options increases patient willingness to try novel therapies. Social media is positively impacting awareness and acceptance of immunotherapy drugs.
Technological: Advances in molecular biology and immuno-oncology are driving the discovery and development of novel anti-CD47 agents. Combination approaches with other immunotherapy drugs hold promise but require further research.The market for anti-CD47 drugs is currently concentrated in North America and Western Europe due to higher acceptance of high-priced cancer drugs in these regions. Both regions have robust healthcare systems capable of absorbing costs of novel therapies in early phase.
The patient pools suffering from hematologic and solid tumors for which anti-CD47 drugs are being evaluated are also sizable in these markets resulting in their increased focus by pharmaceutical companies.The Asia Pacific region excluding Japan is expected to exhibit high growth in the anti-CD47 drugs market over the forecast period owing to improving access to innovative oncology therapies. Rising healthcare expenditure, growing middle-class population and speedy economic growth in countries like China and India are creating opportunities. Initiatives by governments to strengthen local life sciences industry and encourage clinical trials are positives. Increased regional regulatory clarity can further accelerate market evolution in Asia Pacific excluding Japan.
Get this Report in Japanese Language: 抗CD47薬市場
Get this Report in Korean Language: 항 CD47 약물 시장
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
